KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Short-term Investments: 2009-2025

Historic Short-term Investments for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to $5.9 billion.

  • Regeneron Pharmaceuticals' Short-term Investments fell 23.73% to $5.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 billion, marking a year-over-year decrease of 23.73%. This contributed to the annual value of $6.5 billion for FY2024, which is 19.60% down from last year.
  • According to the latest figures from Q3 2025, Regeneron Pharmaceuticals' Short-term Investments is $5.9 billion, which was up 8.47% from $5.5 billion recorded in Q2 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Short-term Investments peaked at $8.1 billion during Q4 2023, and registered a low of $1.8 billion during Q2 2021.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Short-term Investments value was $7.0 billion (recorded in 2023), while the average stood at $6.8 billion.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Short-term Investments surged by 126.87% in 2022 and then crashed by 33.57% in 2025.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Short-term Investments stood at $2.8 billion in 2021, then spiked by 65.05% to $4.6 billion in 2022, then soared by 75.02% to $8.1 billion in 2023, then decreased by 19.60% to $6.5 billion in 2024, then decreased by 23.73% to $5.9 billion in 2025.
  • Its last three reported values are $5.9 billion in Q3 2025, $5.5 billion for Q2 2025, and $5.3 billion during Q1 2025.